Advertisement

Related Videos

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Opportunities to Optimize Cancer Policies Panel Discussion

David A. Hyman, MD, JD, on Inclusive Shared Savings

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Advertisement

Advertisement




Sep
29
Today In Oncology
Adding Targeted Immunotherapy to Pembrolizumab in Recurrent or Metastatic HPV16-Positive Head and Neck Squamous Cell Carcinoma
SRS Is a Reasonable Option for Patients With SCLC and Brain Metastases
Fractionated SRS Approach Improves Outcomes for Patients With Resected Large Brain Metastases
FDA Advisory Committee Votes in Favor of Approval of Multi-Cancer Early Detection Test
Bivalent CAR T-Cell Therapy Shows No Delayed Toxicity and Promising Survival in Recurrent Glioblastoma
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo